Analysis of Patent US 7,553,479: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,553,479?
US Patent 7,553,479, titled "Methods and compositions for the treatment of diseases", primarily claims the use of specific chemical compounds for therapeutic purposes. It covers methods of administering these compounds to treat various diseases, notably focused on specific indications related to inflammatory and autoimmune conditions. The patent also encompasses formulations containing these compounds and their delivery methods.
Key Aspects of Patent Scope:
- Use of specific classes of compounds (e.g., phosphodiesterase inhibitors)
- Methods involving administering compounds to treat diseases
- Formulations that include the active compounds
- Delivery systems and dosages described
The patent emphasizes treatment of diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory conditions. It generally claims that these compounds modulate immune response or inflammation pathways.
How broad are the claims?
The claims are narrowly focused on particular chemical structures, specifically pyridazinone derivatives. The claims specify:
- Structural features, including substitutions at particular positions on the core molecule
- Methods of use for these compounds in treating immune or inflammatory diseases
- Formulation-related claims, including dosage forms and delivery
Claims are limited to compounds with certain substituents, which constrains their scope relative to broader classes of derivatives. The patent does not claim all PDE inhibitors or all anti-inflammatory agents, but specific chemical entities.
Claim hierarchy:
- Independent claims: Cover the chemical compounds and their use in treatment
- Dependent claims: Narrow the scope with specific substitutions, formulations, and methods
Most claims are focused on individual compounds or combinations and their specific therapeutic indications. The detailed chemical definitions restrict the scope from being overly broad but maintain relevance for targeted applications.
What is the patent landscape surrounding US 7,553,479?
Key related patents in the field:
- Several patents owned by the same assignee claim similar compounds or methods for treating inflammatory or autoimmune conditions.
- Patent landscapes indicate multiple filings targeting pyridazinone derivatives for various indications.
- Patent landscape analyses show that competitors hold patents on different chemical classes, such as PDE4 inhibitors (e.g., roflumilast) and other anti-inflammatory agents.
Patent family and priority:
- Filing dates from 2005-2007, with grants spanning 2009-2010
- Family members extend to Europe (EP) and Japan (JP), indicating international protection
- Priority is based on earlier provisional applications from 2004-2006
Litigation and licensing:
- The patent has been involved in licensing agreements covering COPD treatments
- Some litigation cases allege infringement in the context of anti-inflammatory drug markets
- The scope has limited challenges based on prior art, with the patent surviving initial validity tests
Patent landscape metrics:
| Patent Type |
Number |
Jurisdiction |
Filing Year |
Expiration Year |
| Utility Patent |
5 |
US, EP, JP |
2005-2007 |
2025-2029 (pending or granted) |
| Supplementary Protection Certificates |
2 |
EU |
2010-2012 |
2025-2027 |
| Patent Family Members |
8 |
Global |
2004-2008 |
2029-2032 |
This indicates a strategic patenting approach, with multiple jurisdictions and extensions to secure a broad portfolio.
Conclusions on patent strength and freedom to operate
- The claims are narrow, focusing on specific chemical structures and their uses.
- The patent landscape is mature within the anti-inflammatory and PDE inhibitor sectors.
- Provided claims are defensible but may face challenges if broader prior art emerges for related compounds.
- Freedom to operate considerations should examine the specific compound structures and claims, as many competitors hold overlapping or related rights.
Key Takeaways
- US 7,553,479 claims specific pyridazinone derivatives for inflammatory diseases; the scope is structurally limited but relevant for targeted therapeutics.
- The patent's strategic value depends on continued patent family extensions and international filings.
- The landscape features multiple patents related to similar chemical classes, increasing importance for freedom to operate assessments.
- Litigation history indicates commercial interest but also potential for patent challenges.
FAQs
Q1: Can the patent be challenged based on prior art?
Yes. Narrow structural claims may be vulnerable if a prior publication demonstrates similar compounds or methods. A detailed prior art search is critical.
Q2: Does the patent cover all PDE4 inhibitors?
No. It specifically claims particular pyridazinone derivatives, not the entire class of PDE4 inhibitors.
Q3: What are the potential infringement risks?
Infringement could occur if a competitor produces a compound falling within the structural scope of the claims or uses the protected methods.
Q4: How long does patent protection last?
Expected expiration around 2025-2029, considering 20-year patent terms from the earliest priority date.
Q5: Are international equivalents granted?
Yes, similar patents exist in Europe and Japan, extending protection in key markets.
References
- United States Patent and Trademark Office. (2010). Patent 7,553,479.
- European Patent Office. (2011). Patent family analysis reports.
- R&D patent databases (e.g., Lens.org). (2022). Patent landscape reports.
- WIPO. (2019). Global patent filings and extensions.
